|
1. FDA panel backs first multi-cancer blood test: What to know Full story
2. Off-label GLP-1 use jumped fifteenfold in 4 years: 5 notes Full story
3. Payer contract changes and fee schedule updates quietly erode specialty revenue. See where pathology groups are losing it in this webinar.
4. Health system pharmacy keeps 96% of GLP-1 patients on therapy Full story
5. FDA approves Eli Lilly’s weekly insulin injection Full story
6. Embedding AI into oncology operations beyond pilots is the conversation every cancer center is trying to have, and the leaders who’ve moved past pilot are sharing how Nov 4-5 in Chicago. Apply to attend Becker’s Fall Oncology Executive Summit as a reviewer here.
7. FDA flags sterility concerns at major GLP-1 compounder Full story
8. Novo plans 5+ blockbuster drug launches by 2030: 5 things to know Full story
Becker’s Learning Opportunities
7. Contaminated samples can drive false positives and unnecessary treatment. Prevention steps here.
8. Student placements touch HR, infection control and clinical leadership. The Joint Commission weigh in on who owns oversight here.
9. Standardizing utilization review is a change management problem first. NYC Health + Hospitals’ leaders explain why in this webinar.
10. Becker’s upcoming webinars: workforce planning, healthcare large language models and physician-led cancer care. See the sessions here.
Apply to attend complimentary as a guest reviewer here! Opportunity exclusive to those directly employed by a provider organization.
|
.png)
